ABSTRACT
ABSTRACT: This work considers the implications of cloth masks due to the COVID-19 pandemic on suspected plutonium inhalations and dose assessment. In a plutonium inhalation scenario, the greater filtration efficiency for large particles exhibited by cloth masks can reduce early fecal excretion without a corresponding reduction in dose. For plutonium incidents in which cloth masks are worn, urinary excretion should be the preferred method of inferring dose immediately after the inhalation, and fecal excretion should be considered unreliable for up to 10 days.
Subject(s)
COVID-19/prevention & control , Feces/chemistry , Inhalation Exposure/statistics & numerical data , Masks , Occupational Exposure/statistics & numerical data , Plutonium/analysis , Radiation Exposure/statistics & numerical data , Radiation Monitoring , Humans , Inhalation Exposure/prevention & control , Occupational Exposure/prevention & control , Plutonium/pharmacokinetics , Radiation Exposure/prevention & control , Radiation Monitoring/methods , Respiratory System/chemistryABSTRACT
Biokinetics underlies the basis for assessment of internal exposures. This paper develops a biokinetic method on simultaneous intake of radionuclides from multiple intake scenarios in internal exposures. With numerical techniques that transform the whole biokinetics between the coupled and decoupled representations of the same problem, this method applies to coupled biokinetics with complex structures and has no restrictions of practical importance on the number of intake scenarios, the number of intake parent radionuclides and decay products, and the complexity of decay relationships between parent and progeny nuclides. For illustration, this method is applied to an assumed case of mixed inhalation and ingestion of weapon-grade plutonium material for reference workers that is focused on Pu and Am. Due to coupled biokinetics between the direct intake and ingrowth parts in different intake pathways, the multiple intake results (the contents of lungs, daily excretions, and cumulative contents) display richer behaviors as compared to single intake cases. This method benefits both the prospective and retrospective assessment of internal exposures for complex intake cases in actual applications.
Subject(s)
Radiation Exposure , Radioisotopes/administration & dosage , Radioisotopes/pharmacokinetics , Algorithms , Americium/administration & dosage , Americium/pharmacokinetics , Eating , Humans , Inhalation Exposure , Lung/metabolism , Lung/radiation effects , Models, Biological , Occupational Exposure , Plutonium/administration & dosage , Plutonium/pharmacokinetics , Prospective Studies , Radiation Dosage , Radiation Protection , Retrospective Studies , Risk Assessment , SoftwareABSTRACT
NCRP Report 156 describes soluble radionuclide retention kinetics in a wound, segregated into four retention categories: weak (W), moderate (M), strong (S), and avid (A). An alternate single-parameter model, the negative power function, t, is presented in this paper to describe the time behavior of radionuclide retention. With this mathematical description, γ is a single parameter that can be used to assign the wound retention category rapidly. Using the power function description of wound retention, the various wound categories present as straight lines on log scales with different slopes corresponding to the various retention categories. Regression analysis of average retention values in NCRP 156 shows γ = 0.735 ± 0.132, 0.514 ± 0.015, 0.242 ± 0.016, and 0.053 ± 0.023 for the weak, moderate, strong, and avid categories, respectively. A case study is presented (REAC/TS Registry case 1284) where a power function is shown to fit retention data in a Pu/Am hand wound up to 2,000 d (5.4 y) post-accident.
Subject(s)
Radiation Injuries/metabolism , Radioactive Hazard Release , Radioisotopes/adverse effects , Radioisotopes/pharmacokinetics , Wounds, Penetrating/metabolism , Aged , Americium/adverse effects , Americium/pharmacokinetics , Chelating Agents/administration & dosage , Computer Simulation , Humans , Male , Models, Biological , Pentetic Acid/administration & dosage , Plutonium/adverse effects , Plutonium/pharmacokinetics , Radiation Injuries/therapy , Solubility , Thumb/injuries , Thumb/radiation effects , Wounds, Penetrating/therapyABSTRACT
ABSTRACT: The work within identifies the volume of distribution (VD) of plutonium using data from studies in which rats were administered an intravenous bolus injection of 239Pu4+-citrate. The research investigated two separate datasets. Data published by Durbin and colleagues in "Plutonium Deposition Kinetics in Rats" and studies conducted by Lovelace Respiratory Research Institute (LRRI) were examined. The goal of this research was to identify a value of VD consistent with the known biological behavior of plutonium. The identified VD is necessary to develop a physiologically-based pharmacokinetic (PBPK) model. The creation of a PBPK model describing the behavior of plutonium in the body enables the comparison of transfer rates to validate the biokinetic models currently in use for internal dosimetry purposes. The VD of a substance describes the distribution between intracellular and extracellular fluid compartments, providing information such as cellular uptake and protein binding. The VD time profiles and values found using the Durbin data were consistent with known behavior of plutonium. The VD values found using data provided by LRRI were not consistent with known behavior of plutonium; however, the VD time profiles generated may still be of use for PBPK modeling.
Subject(s)
Plutonium , Animals , Kinetics , Plutonium/pharmacokinetics , Radiometry , Rats , Respiratory System/metabolismABSTRACT
To characterize the health effects of incorporated plutonium, many experiments have been conducted using different animal models. These range from (1) applied (tissue uptake/retention determination, decorporation therapy efficacy), (2) fundamental (gene expression, cancer induction), and (3) dosimetry models. In recent years, the use of animals for scientific purposes has become a public concern. The application of the 3Rs - Replace (use of alternative methods or animals not considered capable of experiencing pain, suffering, and distress), Reduce (reduction in animal numbers), and Refine (better animal welfare and minimization of suffering, pain and distress) - has increased to address ethical concerns and legislative requirements. The introduction of novel non-animal technologies is also an important factor as complementary options to animal experimentation. In radiotoxicology research, it seems there is a natural tendency to Replace given the possibility of data reuse obtained from contamination cases in man and animal studies. The creation of "registries" and "repositories" for nuclear industry workers (civil and military) is now a rich legacy for radiotoxicological measurements. Similarly, Reduction in animal numbers can be achieved by good experimental planning with prior statistical analyses of animal numbers required to obtain robust data. Multiple measurements in the same animal over time (external body counting, excreta collection) with appropriate detection instruments also allow Reduction. In terms of Refinement, this has become "de rigueur" and a necessity given the societal and legal concerns for animal welfare. For research in radiotoxicology, particularly long-term studies, better housing conditions within the constraints of radiation protection issues for research workers are an important concern. These are all pertinent considerations for the 3Rs remit and future research in radiotoxicology.
Subject(s)
Animal Testing Alternatives/methods , Plutonium/adverse effects , Plutonium/pharmacokinetics , Animal Experimentation , Animal Rights , Animal Welfare , Animals , Animals, Laboratory , Biomarkers , Gene Expression Regulation/radiation effects , Humans , Models, Statistical , Neoplasms/chemically induced , Radiation Exposure/prevention & control , RadiometryABSTRACT
Chelating agents are administered to treat significant intakes of radioactive elements such as plutonium, americium, and curium. These drugs may be used as a medical countermeasure after radiological accidents and terrorist acts. The administration of a chelating agent, such as Ca-DTPA or Zn-DTPA, affects the actinide's normal biokinetics. It enhances the actinide's rate of excretion, posing a dose assessment challenge. Thus, the standard biokinetic models cannot be directly applied to the chelation-affected bioassay data in order to assess the radiation dose. The present study reviews the scientific literature, from the early 1970s until the present, on the different studies that focused on developing new chelation models and/or modeling of bioassay data affected by chelation treatment. Although scientific progress has been achieved, there is currently no consensus chelation model available, even after almost 50 y of research. This review acknowledges the efforts made by different research groups, highlighting the different methodology used in some of these studies. Finally, this study puts into perspective where we were, where we are, and where we are heading in regards to chelation modeling.
Subject(s)
Chelation Therapy/methods , Radiation Dosage , Radiation Injuries/drug therapy , Americium/chemistry , Americium/pharmacokinetics , Animals , Chelating Agents/therapeutic use , Humans , Models, Animal , Models, Biological , Plutonium/chemistry , Plutonium/pharmacokineticsABSTRACT
After entering the blood, plutonium accumulates mainly in the liver and the bones. The mechanisms leading to its accumulation in bone are, however, completely unknown. We already know that another uptake pathway not involving the transferrin-mediated pathways is suspected to intervene in the case of the liver. Fetuin, a protein playing an important role in bone metabolism, is proposed as a potential transporter of Pu from serum to bone. For the first time, the binding constants of these two proteins (transferrin and fetuin) with tetravalent plutonium at physiological pH (pH 7.0) were determined by using capillary electrophoresis (CE) coupled with inductively coupled plasma mass spectrometry (ICP-MS). Their very close values (log10 KPuTf = 26.44 ± 0.28 and log10 KPuFet = 26.20 ± 0.24, respectively) suggest that transferrin and fetuin could compete to chelate plutonium, either in the blood or directly at bone surfaces in the case of Pu deposits. We performed competition reaction studies demonstrating that the relative distribution of Pu-protein complexes is fully explained by thermodynamics. Furthermore, considering the average concentrations of transferrin and fetuin in the blood, our calculation is consistent with the bio-distribution of Pu observed in humans.
Subject(s)
Fetuins/metabolism , Plutonium/metabolism , Binding, Competitive , Bone and Bones/metabolism , Electrophoresis, Capillary , Humans , Hydrogen-Ion Concentration , In Vitro Techniques , Mass Spectrometry , Plutonium/pharmacokinetics , Protein Binding , Thermodynamics , Transferrin/metabolismABSTRACT
Internal exposure due to inhalation of aerosols depends on the ratio of aerodynamic shape factor (χ) to aerosol mass density (ρ). Inhaled aerosol parameters may differ from the default ρ and χ values provided by the International Commission on Radiological Protection, which are adopted for the assessment of internal exposures. This paper focuses on the influences of χ/ρ on the assessment of internal exposure to Pu for reference workers. Regional deposition fractions are found to decrease with increasing χ/ρ, and larger decreases are observed with smaller activity median aerodynamic diameter aerosols, while the slow clearance fractions (fs) in the tracheobronchial region are more sensitive for larger activity median aerodynamic diameter aerosols. Results from biokinetics calculations reveal that both the time-dependent content (excretion) and cumulative activities are determined mainly for particles initially deposited in the alveolar-interstitial region, while fs affects the local cumulative activities in the tracheobronchial region. χ/ρ is proven to have different influences for aerosols with different activity median aerodynamic diameters. The default χ/ρ values can be used when activity median aerodynamic diameters are greater than 1 µm, while one should pay attention to the value of χ/ρ when activity median aerodynamic diameters are less than 1 µm, where significant influence may be anticipated.
Subject(s)
Aerosols/analysis , Air Pollutants, Radioactive/analysis , Inhalation Exposure/analysis , Models, Biological , Occupational Exposure/analysis , Plutonium/analysis , Adult , Aerosols/pharmacokinetics , Air Pollutants, Radioactive/pharmacokinetics , Digestive System/metabolism , Digestive System/radiation effects , Feces/chemistry , Humans , Male , Plutonium/pharmacokinetics , Respiratory System/metabolism , Respiratory System/radiation effects , Tissue Distribution , Urinalysis , Urinary Bladder/metabolism , Urinary Bladder/radiation effectsABSTRACT
Americium (Am) biodistribution data obtained after wound contamination in rats were analysed to evaluate and quantify the influence of different physicochemical forms of Am in the presence or absence of plutonium (Pu). The biodistribution data were individual Am daily urinary excretion and tissue retention. The data were analysed with STATBIODIS, a statistical tool developed in the laboratory and based on the R language. Non-parametric methods were selected to comply with the data characteristics. Am systemic tissue retention and urinary excretion data were much greater for contamination with soluble physicochemical forms than insoluble forms. Meanwhile, Am relative biodistribution between the main retention tissues (skeleton, liver and kidney) remained the same. Hence, after absorption into blood the radionuclide behaviour was independent of the physicochemical form. The presence of Pu did not change the Am biodistribution. Comparisons of the biodistribution data from the laboratory with mean values published by other laboratories showed that soluble to moderately soluble forms of Am resulted in similar urine excretion after contamination, whether it was intravenous, intramuscular, subcutaneous injection or incision. Findings from this work will contribute to improve the understanding and interpretation of wound contamination cases with different physicochemical forms and mixtures of actinides including Am.
Subject(s)
Americium/pharmacokinetics , Plutonium/pharmacokinetics , Radiation Injuries, Experimental/metabolism , Tissue Distribution/radiation effects , Animals , Data Interpretation, Statistical , Male , Rats , Rats, Sprague-DawleyABSTRACT
The US Transuranium and Uranium Registries is a human tissue program that collects tissues posthumously from former nuclear workers and radiochemically analyzes them for actinides such as plutonium, americium, and uranium. It was established in 1968 with the goal of advancing science and improving the safety of future workers. Roundtable participants recalled various aspects of this multidisciplinary research program, from establishing consistent autopsy protocols to comparing the registries' findings to those of other programs, such as the historical beagle dog studies and the Russian Radiobiological Human Tissue Repository. The importance of meeting ethical and legal requirements, including written consent forms, was emphasized, as was the need to know whether workers were exposed to nonradiological hazards such as beryllium or asbestos. At Rocky Flats, a bioassay program was established to follow workers after they terminated employment. The resulting data continue to help researchers to improve the biokinetic models that are used to estimate intakes and radiation doses. After 50 y, the US Transuranium and Uranium Registries continues to contribute to our understanding of actinides in humans, which is a testament to the vision of its founders, the generosity of its tissue donors, and the many dedicated scientists who have worked together to achieve a common goal.
Subject(s)
Occupational Diseases/etiology , Occupational Exposure/analysis , Plutonium/pharmacokinetics , Radiation Injuries/etiology , Registries/statistics & numerical data , Uranium/pharmacokinetics , Animals , Dogs , Follow-Up Studies , Humans , Occupational Diseases/epidemiology , Occupational Exposure/adverse effects , Plutonium/adverse effects , Plutonium/analysis , Radiation Injuries/epidemiology , Tissue Distribution , United States/epidemiology , Uranium/adverse effects , Uranium/analysisABSTRACT
Physicochemical properties of actinides highly influence internal intake and biodistribution. An a priori knowledge of the dissolution properties of compounds involved in accidental exposure would be of great help in early dose assessment. However, this information is rarely available, leading to difficulties in interpreting excretion data from contaminated victims. We developed an in vitro acellular assay to predict in vivo bioavailability of actinides and improve medical handling of the victims. Various actinides of different physicochemical properties were used to validate the reliability of the assay to mimic in vivo behavior of the contaminants. Our assay was designed as a dynamic muticompartmental system in which an agarose gel represents the retention compartment of actinides and a dynamic phase the transfer compartment. Relevant physiological conditions were obtained by introducing various components both in the static and dynamic phases. The proposed model may provide a good prediction of in vivo behavior and could be used as a first assessment to predict the fraction of actinides that could be potentially transferred from retention compartments, as well as the fraction available to chelating drugs.
Subject(s)
Americium/pharmacokinetics , Biological Assay , Chelating Agents/pharmacology , Plutonium/pharmacokinetics , Uranium/pharmacokinetics , Biological Availability , Body Fluids/metabolism , Bone and Bones/metabolism , Citrates/pharmacokinetics , Colloids , Lung/metabolism , Nitrates/pharmacokinetics , Pentetic Acid/pharmacology , Pyridones/pharmacology , Radiation Exposure , Radioactive Hazard Release , TransferrinABSTRACT
The slow dissolution rate of material deposited in the lung plays a key role in determining the eventual radiation dose received by the lung. It is therefore of great importance to establish a reliable value for this parameter, to incorporate into the latest Mayak Worker Dosimetry System (MWDS-2016). Disparate values have been obtained for the slow dissolution rate of plutonium nitrate. A volunteer study performed by Public Health England (PHE) and an analysis of United States Transuranium and Uranium Registries (USTUR) case 0269 have yielded slow dissolution rates in the region of 10-40 × 10-4 d-1. However, autopsies performed on 20 Mayak workers, exposed predominantly to nitrates, have resulted in estimates of slow dissolution rates of around 2.4 × 10-4 d-1. Three hypotheses have been proposed to explain this discrepancy: (1) a slower dissolution rate in the interstitium, (2) a third exponential component in the dissolution function and (3) a small component of oxide in the aerosol to which Mayak 'nitrate' workers were exposed. This paper describes tests of these competing hypotheses. Bayesian methods have been applied to the following datasets: PHE volunteer data; Beagle dog data; USTUR cases and Mayak worker data. It is concluded that a mixture of oxide and nitrate material, with the oxide forming ~14% of the intake, best describes the Mayak dissolution rate, without introducing values for other parameters which conflict with other studies.
Subject(s)
Air Pollutants, Radioactive/analysis , Aorta, Thoracic/metabolism , Lung/metabolism , Lymph Nodes/metabolism , Nitrates/pharmacokinetics , Occupational Exposure/analysis , Plutonium/pharmacokinetics , Animals , Aorta, Thoracic/radiation effects , Bayes Theorem , Dogs , England , Humans , Lung/radiation effects , Lymph Nodes/radiation effects , Male , Nitrates/analysis , Nuclear Warfare , Organ Specificity , Plutonium/analysis , Radiation Dosage , Tissue DistributionABSTRACT
A recently proposed system of models for plutonium decorporation (SPD) was developed using data from an individual occupationally exposed to plutonium via a wound [from United States Transuranium and Uranium Registries (USTUR) Case 0212]. The present study evaluated the SPD using chelation treatment data, urine measurements, and post-mortem plutonium activities in the skeleton and liver from USTUR Case 0269. This individual was occupationally exposed to moderately soluble plutonium via inhalation and extensively treated with chelating agents. The SPD was linked to the International Commission on Radiological Protection (ICRP) Publication 66 Human Respiratory Tract Model (HRTM) and the ICRP Publication 30 Gastrointestinal Tract model to evaluate the goodness-of-fit to the urinary excretion data and the predictions of post-mortem plutonium retention in the skeleton and liver. The goodness-of-fit was also evaluated when the SPD was linked to the ICRP Publication 130 HRTM and the ICRP Publication 100 Human Alimentary Tract Model. The present study showed that the proposed SPD was useful for fitting the entire, chelation-affected and non-affected, urine bioassay data, and for predicting the post-mortem plutonium retention in the skeleton and liver at time of death, 38.5 years after the accident. The results of this work are consistent with the conclusion that Ca-EDTA is less effective than Ca-DTPA for enhancing urinary excretion of plutonium.
Subject(s)
Air Pollutants, Radioactive/urine , Chelating Agents/therapeutic use , Edetic Acid/therapeutic use , Inhalation Exposure , Models, Biological , Pentetic Acid/therapeutic use , Plutonium/urine , Radiation Injuries/prevention & control , Air Pollutants, Radioactive/pharmacokinetics , Bone and Bones/metabolism , Gastrointestinal Tract/metabolism , Humans , Liver/metabolism , Occupational Exposure , Plutonium/pharmacokinetics , Respiratory System/metabolismABSTRACT
Individuals with significant intakes of plutonium (Pu) are typically treated with chelating agents, such as the trisodium salt form of calcium diethylenetriaminepentaacetate (CaNa3-DTPA, referred to hereafter as Ca-DTPA). Currently, there is no recommended approach for simultaneously modeling plutonium biokinetics during and after chelation therapy. In this study, an improved modeling system for plutonium decorporation was developed. The system comprises three individual model structures describing, separately, the distinct biokinetic behaviors of systemic plutonium, intravenously injected Ca-DTPA and in vivo-formed Pu-DTPA chelate. The system was linked to ICRP Publication 100, "Human Alimentary Tract Model for Radiological Protection" and NCRP Report 156, Development of a Biokinetic Model for Radionuclide-Contaminated Wounds and Procedures for Their Assessment, Dosimetry and Treatment." Urine bioassay and chelation treatment data from an occupationally-exposed individual were used for model development. Chelation was assumed to occur in the blood, soft tissues, liver and skeleton. The coordinated network for radiation dosimetry approach to decorporation modeling was applied using a chelation constant describing the secondorder, time-dependent kinetics of the in vivo chelation reaction. When using the proposed system of models for plutonium decorporation, a significant improvement of the goodness-of-fit to the urinary excretion data was observed and more accurate predictions of postmortem plutonium retention in the skeleton, liver and wound site were achieved.
Subject(s)
Chelating Agents/chemistry , Models, Chemical , Pentetic Acid/chemistry , Plutonium/chemistry , Biological Assay , Chelating Agents/administration & dosage , Chelating Agents/pharmacokinetics , Humans , Models, Biological , Occupational Exposure , Pentetic Acid/administration & dosage , Pentetic Acid/pharmacokinetics , Plutonium/pharmacokinetics , Plutonium/urine , Postmortem Changes , Radiation Dosage , Tissue DistributionABSTRACT
Differences in results from the new Mayak Worker Dosimetry System (MWDS-2016) vs the previous MWDS-2013 are described. Statistical characteristics are shown for the distribution of accumulated absorbed doses to organs for 8340 workers with bioassay data. Differences in mean values of accumulated doses and their relative standard uncertainties calculated by MWDS-2016 and MWDS-2013 were analysed separately for various types of industrial compounds of plutonium, specifically nitrates, mixtures and oxides. Within the range of accumulated doses >1 mGy, lung doses for nitrates and mixtures decreased by 41 and 15%, respectively, and remained at the same level for oxides. Accumulated liver doses within the range >1 mGy increased for nitrates and mixtures by 13 and 8%, respectively, and decreased for oxides by 7%.
Subject(s)
Liver/radiation effects , Lung/radiation effects , Occupational Exposure/adverse effects , Plutonium/adverse effects , Radiation Monitoring/methods , Biological Assay , Gamma Rays , Humans , Liver/metabolism , Lung/metabolism , Plutonium/pharmacokinetics , Radiation Dosage , Tissue DistributionABSTRACT
The bioassay data collected from several workers involved in 238Pu inhalation incidents have been analysed using the most recent biokinetic models described in the Occupational Intakes of Radionuclides (OIR) series of publications. Although all exposures were thought to be to 238Pu oxides, the observed urinary excretion patterns differed in different inhalation incidents. The urinary excretion from individuals involved in one of the incidents increased steadily with time, peaking around two to three years before decreasing. This pattern is described in Part 4 of the OIR series using the '238PuO2, ceramic' model. This non-monotonic behaviour, explained as being due to fragmentation and dissolution, was not specific to the incident, but observed in other incidents. The urinary excretion data collected from individuals involved in another incident showed dissolution behaviour between Type M and Type S. Finally, the bioassay data from yet another incident showed a pattern that appears to represent behaviour more insoluble than Type S, which is possibly a result of self-heating due to the decay heat from 238Pu. The urinary excretion patterns and corresponding dose coefficients have been calculated and compared.
Subject(s)
Models, Biological , Occupational Exposure/analysis , Plutonium/pharmacokinetics , Biological Assay , Humans , UrinalysisABSTRACT
Epidemiological studies have shown that the main risk arising from exposure to plutonium aerosols is lung cancer, with other detrimental effects in the bone and liver. A realistic assessment of these risks, in turn, depends on the accuracy of the dosimetric models used to calculate doses in such studies. A state-of-the-art biokinetic model for plutonium, based on the current International Commission on Radiological Protection biokinetic model, has been developed for this purpose in an epidemiological study involving the plutonium exposure of Mayak workers in Ozersk, Russia. One important consequence of this model is that the lung dose is extremely sensitive to the fraction (fb) of plutonium, which becomes bound to lung tissue after it dissolves. It has been shown that if just 1% of the material becomes bound in the bronchial region, this will double the lung dose. Furthermore, fb is very difficult to quantify from experimental measurements. This paper summarizes the work carried out thus far to quantify fb. Bayesian techniques have been used to analyze data from different sources, including both humans and dogs, and the results suggest a small, but nonzero, fraction of < 1%. A Bayesian analysis of 20 Mayak workers exposed to plutonium nitrate suggests an fb between 0 and 0.3%. Based on this work, the International Commission on Radiological Protection is currently considering the adoption of a value of 0.2% for the default bound fraction for all actinides in its forthcoming recommendations on internal dosimetry. In an attempt to corroborate these findings, further experimental work has been carried out by the US Transuranium and Uranium Registries. This work has involved direct measurements of plutonium in the respiratory tract tissues of workers who have been exposed to soluble plutonium nitrate. Without binding, one would not expect to see any activity remaining in the lungs at long times after exposure since it would have been cleared by the natural process of mucociliary clearance. Further supportive study of workers exposed to plutonium oxide is planned. This paper ascertains the extent to which these results corroborate previous inferences concerning the bound fraction.
Subject(s)
Bayes Theorem , Lung/metabolism , Models, Biological , Occupational Exposure/analysis , Plutonium/analysis , Animals , Dogs , Humans , Lung/radiation effects , Plutonium/pharmacokinetics , Radiation Dosage , Tissue DistributionABSTRACT
Following inhalation of an aerosol of relatively insoluble particles, it is usually found that the fractional dissolution rate of material retained in the lungs decreases with time, and the amount remaining undissolved can be represented simply by a decreasing exponential function with two or more components. A few exceptions are known, in which the dissolution rate increases with time. The most important in the context of radiological protection is probably that of 238Pu dioxide. Several published comprehensive data sets, from animal studies and accidental human exposures, have been analysed using the Human Respiratory Tract Model (HRTM) of the International Commission on Radiological Protection. The HRTM contains a simplified representation of particle dissolution in the respiratory tract, suitable for routine radiological protection purposes. Still, it was found to have sufficient flexibility to represent the measurement data in most of these cases. Although the 238Pu dioxide showed a wide range of behaviour in the different studies, there was good agreement between the absorption behaviour modelled for two studies involving 'ceramic' 238Pu dioxide as used in spacecraft radioisotope thermoelectric generators: a long-term experimental study in dogs and an accidental exposure involving a group of workers.
Subject(s)
Lung/metabolism , Oxides/pharmacokinetics , Plutonium/pharmacokinetics , Aerosols , Animals , Humans , Models, AnimalABSTRACT
The aim of this study is to present several approaches that have been used to model the behavior of radioactive materials (specifically Pu) in contaminated wounds. We also review some attempts by the health physics community to validate and revise the National Council on Radiation Protection and Measurements (NCRP) 156 biokinetic model for wounds, and present some general recommendations based on the review. Modeling of intake via the wound pathway is complicated because of a large array of wound characteristics (e.g. solubility and chemistry of the material, type and depth of the tissue injury, anatomical location of injury). Moreover, because a majority of the documented wound cases in humans are medically treated (excised or treated with chelation), the data to develop biokinetic models for unperturbed wound exposures are limited. Since the NCRP wound model was largely developed from animal data, it is important to continue to validate and improve the model using human data whenever plausible.
Subject(s)
Plutonium/pharmacokinetics , Plutonium/poisoning , Radiation Injuries/blood , Wounds, Penetrating/blood , Accidents, Occupational , Biological Assay , Humans , Models, Biological , Occupational Exposure/analysis , Radioactive Hazard ReleaseABSTRACT
After a chelation treatment, assessment of intake and doses is the primary concern of an internal dosimetrist. Using the urinary excretion data from two actual wound cases encountered at Los Alamos National Laboratory (LANL), this paper discusses several methods that can be used to interpret intakes from the urinary data collected after one or multiple chelation treatments. One of the methods uses only the data assumed to be unaffected by chelation (data collected beyond 100 d after the last treatment). This method, used by many facilities for official dose records, was implemented by employing maximum likelihood analysis and Bayesian analysis methods. The impacts of an improper assumption about the physicochemical behavior of a radioactive material and the importance of the use of a facility-specific biokinetic model when available have also been demonstrated. Another method analyzed both the affected and unaffected urinary data using an empirical urinary excretion model. This method, although case-specific, was useful in determining the actual intakes and the doses averted or the reduction in body burdens due to chelation treatments. This approach was important in determining the enhancement factors, the behavior of the chelate, and other observations that may be pertinent to several DTPA compartmental modeling approaches being conducted by the health physics community.